Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028

Kailera Therapeutics, Inc. (NASDAQ: KLRA) has completed enrollment in its KaiNETIC global Phase 3 clinical program, which includes three trials assessing ribupatide injection (KAI-9531) for obesity treatment. This investigational drug targets individuals with a BMI of 35 kg/m² or higher. Topline data from the trials is now anticipated in mid-2028.